ethyl 4-[(2-oxospiro[1H-pyrido[2,3-d][1,3]oxazine-4,4'-piperidine]-1'-yl)methyl]piperidine-1-carboxylate | 1370352-56-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: ethyl 4-[(2-oxospiro[1H-pyrido[2,3-d][1,3]oxazine-4,4'-piperidine]-1'-yl)methyl]piperidine-1-carboxylate
• CAS: 1370352-56-9
• 化学式: C₂₀H₂₈N₄O₄
• 分子量: 388.467
• InChiKey: BOMYBXNCZBOHBY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  84
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ethyl 4-[(2-oxospiro[1H-pyrido[2,3-d][1,3]oxazine-4,4'-piperidine]-1'-yl)methyl]piperidine-1-carboxylate 、 碘甲烷 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 Ethyl 4-[(1'-methyl-2'-oxospiro[piperidine-4,4'-pyrido[2,3-d][1,3]oxazine]-1-yl)methyl]piperidine-1-carboxylate
  参考文献：
  名称：

  Identification of N-substituted 8-azatetrahydroquinolone derivatives as selective and orally active M1 and M4 muscarinic acetylcholine receptors agonists

  摘要：

  We designed and synthesized N-substituted 8-azatetrahydroquinolone derivatives as selective M-1 and M-4 muscarinic acetylcholine receptors agonists. Optimization of selected derivatives led to the discovery of compound 7 as a highly potent M-1 and M-4 agonist with weak hERG inhibition. Oral administration of compound 7 improved psychosis-like behavior in rats. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.013
• 作为产物：
  描述：

  4-甲酰基哌啶-1-羧酸乙酯 、 螺[哌啶-4,4-[4h]吡啶并[2,3-d][1,3]噁嗪]-2(1h)-酮 在 三乙酰氧基硼氢化钠 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 ethyl 4-[(2-oxospiro[1H-pyrido[2,3-d][1,3]oxazine-4,4'-piperidine]-1'-yl)methyl]piperidine-1-carboxylate
  参考文献：
  名称：

  Identification of N-substituted 8-azatetrahydroquinolone derivatives as selective and orally active M1 and M4 muscarinic acetylcholine receptors agonists

  摘要：

  We designed and synthesized N-substituted 8-azatetrahydroquinolone derivatives as selective M-1 and M-4 muscarinic acetylcholine receptors agonists. Optimization of selected derivatives led to the discovery of compound 7 as a highly potent M-1 and M-4 agonist with weak hERG inhibition. Oral administration of compound 7 improved psychosis-like behavior in rats. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.013